The New Amgen CEO and the Challenges He Faces, Must Win Investors With Payouts, Deals: Analysts

Bob Bradway hasn't even taken the helm at Amgen Inc (AMGN.O), but the clock is already ticking on how the world's largest biotech will compete with rivals, including Big Pharma. Powerful value investors, who helped push up the stock 26 percent since it took a page from traditional drug companies last year with a dividend payout and stock buyback plan, are clamoring for more. But other shareholders still hope Amgen can keep growing, possibly by spending some of the firm's pile of cash to bulk up the pipeline of new drugs.

Back to news